Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024
The Company expects Net revenue between $445.0 million and $470.0 million, an increase of approximately 3% to 9% year-over-year, as compared to net revenue of $433.1 million for the year ended December 31, 2023. Net income (loss) between ($10.6) million and $4.6 million and adjusted net income (loss) between ($8.1) million and $7.1 million.